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Abstract	
Transgenic mice overexpressing the high mobility group A (HMGA) genes, Hmga1 or Hmga2 
develop pituitary tumours and their overexpression is also a frequent finding in human pituitary 
adenomas. In some cases, increased expression of HMGA2 but not that of HMGA1 is consequent to 
genetic perturbations. However, recent studies show that down-regulation of microRNA (miRNA), 
that contemporaneously target the HMGA1 and HMGA2 transcripts, are associated with their 
overexpression. In a cohort of primary pituitary adenoma we determine the impact of epigenetic 
modifications on the expression of HMGA-targeting miRNA. For these miRNAs, chromatin 
immunoprecipitations showed that transcript down-regulation is correlated with histone tail 
modifications associated with condensed silenced genes. The functional impact of epigenetic 
modification on miRNA expression was determined in the rodent pituitary cell line, GH3. In these 
cells, histone tail, miRNA-associated, modifications were similar to those apparent in human adenoma 
and likely account for their repression. Indeed, challenge of GH3 cells with the epidrugs, zebularine 
and TSA, led to enrichment of the histone modification, H3K9Ac, associated with active genes, and 
depletion of the modification, H3K27me3, associated with silent genes and re-expression of HMGA-
targeting miRNA. Moreover, epidrugs challenges were also associated with a concomitant decrease in 
hmga1 transcript and protein levels and concurrent increase in bmp-4 expression. These findings 
show that the inverse relationship between HMGA expression and targeting miRNA is reversible 
through epidrug interventions. In addition to showing a mechanistic link between epigenetic 
modifications and miRNA expression these findings underscore their potential as therapeutic targets 
in this and other diseases.                     
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Introduction	
	
Human pituitary adenomas are common intracranial neoplasms that show subtype-specificity, 
reflecting the phenotypic characteristics that define their cognate differentiated cellular counterparts. 
[1,2] However, their growth and endocrine characteristics are frequently exaggerated, and they fail to 
respond appropriately to homeostatic control and regulatory mechanisms that characterizes their 
normal cellular counterparts. [2]   
In common with most other tumour types the genesis of pituitary tumours is consequent to the 
combined contribution of genetic and epigenetic aberration, targeting the genome and epigenome 
respectively.[3,4,2,5]  The relative contributions of these aberrations, their order of appearance, and 
the way in which their effects are manifest are largely unknown, however, specific aberration, be they 
genetic or epigenetic, are either common or particular to an adenoma subtype(s). [6,5,7] Moreover, 
the demarcation between genetic and epigenetic aberrations are perhaps less precise than initial 
findings suggested. In this context, we now know that the GNAS1 gene (the gsp oncogene), is 
activated or inappropriately expressed, either through mutation or relaxation of imprinting in growth 
hormone secreting pituitary adenomas. [8] Similarly, early reports describing  inappropriate 
expression of the  high mobility group A gene (HMGA2) showed this to be associated with genetic 
change, apparent as chromosomal amplification or re-arrangement. [9,10] However, more recent 
investigations now describe association between microRNA (miRNA) and the inappropriate 
expression of HMGA2 and also that of the HMGA1 gene.  [11]  In these cases, increase in HMGA1 
and HMGA2 expression is associated with loss or significantly reduced expression of miRNA that 
target these gene transcripts.  
MiRNAs play important roles in a range of essential, albeit diverse, cellular processes, that 
include differentiation, cell growth and cell death. [12] They comprise a class of endogenous, non-
protein coding, single-stranded RNAs, that range in size from 20 to 25 nucleotides and repress 
posttranscriptional protein synthesis by pairing to the 3׳ -untranslated regions of target mRNA(s) and, 
dependent on the integrity of the pairing, promotes degradation of the mRNA target transcript or 
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repress post-transcriptional translation. [13]  Reports of their inappropriate expression in disparate 
tumour types is persuasive with respect to their role in tumourigenesis. In a pituitary tumour context 
several recent reports describe inappropriate miRNA expression patterns together with identification 
of their putative mRNA targets. The mechanistic potential of miRNAs to elicit tumour suppressor 
activity in a pituitary context was first reported by Palmieri and co-workers. [11]  They identified loss 
or significantly reduced expression of multiple miRNAs that target the HMGA1 and HMGA2 
transcripts across each of the major pituitary adenoma subtypes. Moreover, heterologous expression 
of these miRNA in pituitary cell lines inhibited cell proliferation, colony forming activity (CFE) and 
leads to decrease in cell viability. [11]  In a follow on study, in this case interrogating GH secreting 
adenoma, multiple miRNA that target the HMGA and the E2F1 transcripts were also identified and 
their heterologous expression were also associated with similar end-points. [14]   More recent studies, 
of inappropriate miRNA expression profile in this case in GH and ACTH secreting adenomas also 
show that particular miRNA can elicit growth suppressive actions in vitro, and also in, in vivo model 
systems. [15,16]  Collectively, these reports portend the therapeutic potential of miRNA through 
either restoration or inhibition of their expression in tumour cells. 
Despite a burgeoning literature describing the inappropriate expression of miRNAs in 
pituitary adenomas, and still more recent studies that reveal the impact of these non-coding RNAs on 
biologically relevant endpoints, our understanding of their transcriptional regulation per se is 
incomplete. However, as with conventional protein-coding genes, it is apparent that the same 
regulatory mechanisms regulate their expression. [17] In these cases, expression of miRNAs can be 
silenced through inappropriate hypermethylation of CpG islands and/or by histone modifications. [18] 
In this report we explore, for the first time, the potential impact of epigenetic modifications on the 
expression of miRNA that target the HMGA1 and HMGA2 transcripts in primary pituitary adenomas. 
Moreover, to determine the functional impact of epigenomic modifications on miRNA expression, 
epidrug challenges were employed to restore their expression and to explore their sequelae for the 
HMGA1 transcript and its protein product. 
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We now show, in human pituitary adenomas that HMGA-targeting miRNA are principally 
repressed through histone modification that are commonly associated with gene silencing. Moreover, 
the rodent homologues of these miRNA are also repressed in association with similar histone tail 
modifications. Epidrug mediated reversal of these modifications restores their expression and is 
associated with depletion of their target transcript in these cells. The potential of pharmacological 
manipulation of the epigenome either alone or in combinations with more conventional therapeutic 
options  offers exciting prospect for future medical management of these and other tumour types.        
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Materials and Methods 
Cell Culture: 
GH3 a rat pituitary cell line (CCL-82.1: American Type Culture Collection, Manassas, VA) in the 
somatolactotroph lineage were cultured in DMEM (Biosera, Ringmer, UK), supplemented with 10% 
fetal bovine serum, 4µg/mL Gentamycin (Sigma-Aldrich, Dorset, UK) and 2µg/mL Ampicillin 
(Sigma-Aldrich) in a 5% CO2 atmosphere at 37°C and as previously described. [19] Cells in the 
current study had undergone less than 15 passages.  
Primary Tissue: 
For some of the described investigations we used, as controls, DNA and RNA extracted from normal 
rat pituitaries. The strain of these pituitaries was Sprague Dawley, and they were obtained from a 
commercial source (Charles River, Kent, UK).  
Human Tissue Samples: 
Primary pituitary adenomas, comprising each of the major subtypes were graded according to a 
modified Hardy classification as described previously. [20] The subtypes comprised,  GH-secreting 
tumours (GH),  all of which were grade 2 macroadenomas, Prolactinomas (PRL) were grade 1 
microadenomas, and also grade 2 and 3 macroadenomas, Corticotrophinoma (ACTH) were grade 2 
macroadenomas, Non-functioning adenomas (NF) were all grade 2 and 3 macroadenomas and their 
clinical characteristics have been described previously by us. [20] As control we used post-mortem 
normal pituitaries, acquired within 12 hours of death. However, a caveat associated with these 
apparent normal controls and indeed of the normal rat pituitary in the studies employing GH3 cells is 
that the comparisons represent essentially monoclonal (tumour cells) populations with an admix of 
cells that comprise the normal gland. Therefore, the findings and their interpretation should be viewed 
and regarded in the light of these limitations.  Primary human tissue was stored at -80°C before use. 
Only those adenomas were tumour cells made up at least 80% of the specimen, as determined at 
surgery, and confirmed by neuropath logical assessment, were used in the study. Before the described 
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extraction protocols, tumours and normal pituitaries were freeze fractured using a biopulveriser 
(BioSpec Products, Inc. Bartlesville, OK) to achieve a homogenous mixture of cells. The absolute 
number of primary tumours analyzed for each of the variables is shown in the figures and comprised 5 
GH, 5 PRL, 4 ACTH and 9 NF adenomas. Tumour tissue was obtained with informed consent, and all 
studies were performed with institutional ethical approval. 
Chemicals: 
The cytidine deaminase inhibitor and DNA demethylating agent, zebularine [1-(-D-ribofuranosyl)-
1,2-dihydropyrimidin-2-one], and histone deacetylase inhibitor, Trichostatin A (TSA) were obtained 
from Sigma-Aldrich. Stock solutions were prepared as previously described and stored in accordance 
to the manufacturer’s instructions. [19] GH3 cells were seeded into six-well plates and incubated 
overnight in growth media and subsequently challenged for 48hrs with either zebularine, or TSA 
alone, or in combination at the doses shown in the figures and with a single refreshment after 24hrs. 
Cells were then harvested after a total of 72hrs in culture. All experiments were repeated thrice with 
triplicate determinations. 
Bioinformatic identification of miRNA transcription start sites: 
The miRNA selected for investigation in this study are those identified in a previous report, which 
also describes their specificity for the HMGA1 and HMGA2 transcripts in primary pituitary adenomas. 
[11] In these cases we focused our investigation on miR-16, miR-26b, mirR-34b miR-196a2 and let-
7a (Table 1, supplemental data) since these miRNA have been shown to target HMGA1 and HMGA2 . 
In addition we included, as internal control, miR-320 that shows increased expression in GH secreting 
adenoma. [14]  MiRNA sequences, their specific transcription start sites and, where present, their 
associated CpG islands, were determined using the, miRBase, miRStart and miRT databases. [21-23] 
Expression Analysis: 
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MiRNA were extracted from, Sprague Dawley rat pituitaries, GH3 cells, primary pituitary adenomas 
and post-mortem normal pituitaries using the mirPremier miRNA extraction kit (Sigma-Aldrich) in 
accordance with the manufacturer’s instructions and stored at -80°C prior to analysis.   
Stem-Loop RT-PCR: 
Reverse transcription for each of the mature miRNA [described above and first identified in [14,11]] 
was performed using stem-loop primers that were specific for each miRNA and also for RNU6B as 
endogenous control for quantitative RT-PCR expression and as described previously. [24,25] Stem-
Loop primer sequence and their specific miRNA targets are described in supplemental Table 1 
(Supplemental data).   cDNA was synthesized using 200U of Maloney mouse leukemia virus reverse 
transcriptase (Promega, Southampton, UK) according to the manufacturer’s instructions and as 
previously described. [26] 
Quantitative RT-PCR: 
The primer sequences for real time quantification are shown in Table 1 (Supplemental Table 1) using 
conditions previously described. [19]  All samples were analyzed in triplicate to account for technical 
variation. The target gene transcripts for the miRNA were normalized to their respective endogenous 
controls (see above and Supplemental Table 1). For analysis of HMGA1 and BMP-4 expression, 
transcript expression was normalized to GAPDH. [24,27,11] Relative quantification was carried out 
using 2-ΔΔCT threshold method.  
Bisulphite conversion and pyrosequencing: 
DNA was extracted from normal rat pituitaries, the GH3 cell line, primary pituitary adenomas and 
post mortem normal pituitaries. For the cell lines experiments extractions were performed before and 
after drug manipulations as previously described. [28] Bisulphite conversions were performed using 
EZ DNA Methylation-Gold Kit and the converted DNA eluted from the column and stored at -20°C 
as previously described. [29] The methylation status of selected miRNA associated CpG islands were 
determined using primers within bona fide CpG islands associated with the individual miRNA and as 
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determined by miRStart and miRT analysis [22,23,21]. Sequences for analysis were imported into 
PyroMark Assay Design 2.0 software for primer design of sodium bisulphite-converted DNA 
(Qiagen, Crawley, UK) and in the majority of cases encompassed 5-8 CpG dinucleotides (Table 1, 
Supplemental data).  PCR amplifications and pyrosequencing was performed as previously described 
by us. [6]  
Chromatin Immunoprecipitation (ChIP) analysis for histone modifications: 
ChIP analysis was performed employing ChIP-IT Express Enzymatic Kit (Active Motif, Rixensart, 
Belgium) following the manufacturer’s instructions and as we described previously.[20]  Briefly, after 
DNA-Protein crosslinking in 1% formaldehyde (Sigma Aldrich), cells or primary tissues were lysed 
in ice-cold buffer, supplemented with protease inhibitor cocktail and phenyl methane sulfonyl fluoride 
(PMSF), after which cells or primary tissues were homogenized to release the nuclei. After 
resuspension in digestion buffer, supplemented with inhibitor cocktail and an enzymatic shearing 
cocktail (Active Motif) the samples were centrifuged. The supernatant comprised the sheared 
chromatin for immune-precipitation and a fraction (10%) set aside as input chromatin prior to 
antibody affinity manipulations and subsequent reversal of crosslinking.  The histone modification 
assessed on the basis of their antibody affinity were those specific for active gene expression, 
H3K9Ac [30] and for DNA methylation-independent gene silencing H3K27Me3 [31]. Antibodies 
were obtained from Abcam (Cambridge, UK) and have been described previously [19]. After 
overnight incubation, precipitation was achieved using protein-G-magnetic bead separation (Active 
Motif), as described previously. [19] After elution and reversal of cross linking the chromatin was 
subject to proteinase K digestion and DNA was purified using GenElute PCR (Sigma-Aldrich). DNA 
was probed for enrichment using primers specific for individual miRNA (supplemental Table 1) by 
quantitative PCR. In these cases primers were designed to regions associated with transcription start 
sites and identified employing the on line databases previously described. [23,22] Percentage 
enrichment were determined relative to input DNA and was calculated as 100 X 2-(CT adjusted input-CT 
immune-precipitated). Input DNA CT was adjusted from 10% to 100% by subtracting 3.322 CT or Log2. 
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HMGA1 Enzyme Linked Immunosorbant Assay (ELISA): 
Quantitative expression of intracellular hmga1was determined by ELISA specific for the rodent 
homologue of HMGA1 (Cusabio Biotech Co., Wuhan, China) according to the manufacturer’s 
protocol and following the epidrug challenges described above. Lysates, from each of the tissues 
(normal rat pituitaries) or cell pellets (GH3 cells), was first quantified using a Bicinchoninic assay and 
as described previously [32]. Briefly, 1.5 mg/mL total protein lysate was used for each determination 
and assessed against an internal standard curve of known hmga1 concentrations. Hmga1 standards 
and samples were pipetted into individual wells and incubated with a biotinylated anti-rat hmga1 
antibody. After washing, to remove unbound biotinylated antibody, the bound antibody was detected 
by an horseradish peroxidase-conjugated streptavidin and 3,3׳,5,5 ׳ tetramethylbenzidine visualization 
strategy. After addition of the stop solution, the intensity of the color was measured at 450 nm. The 
assay has a reported sensitivity of approximately 7.8pg/mL, and all experiments were repeated at least 
three times. 
 
RESULTS 
Histone modifications associated with HMGA transcript-targeting miRNA in primary pituitary 
adenomas: 
In a cohort of primary pituitary tumours, comprising each of the major adenoma subtypes we 
determined the expression status of miRNA shown previously to target the HMGA1 and HMGA2 gene 
transcripts in these tumour types. [11] For each of the adenomas we also determined the histone tail 
modification commonly associated with active, H3K9Ac, and repressed genes, H3K27Me3. The 
findings for, miR-26b, miR-196a-2 and let-7a are presented in Figure 1 and for miR-16 and miR34b 
as supplemental data (supplemental data, Figure, S1). In these cases and for each of the miRNA 
robust expression was apparent in the post- mortem normal pituitaries. The majority of adenomas, 
irrespective of their subtype, showed reduced expression for each of these miRNA (Figure 1A and 
supplemental Figure S1A) and similar findings for their expression have been reported previously. 
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[11] In those cases where we observed decrease in miRNA transcript levels, ChIP analysis showed, in 
the majority of cases, depletion of the modification associated with active genes, H3K9Ac, and 
enrichment for the modification associated with silences genes, H3K27me3, relative to post-mortem 
pituitaries (Figure 1B and 1C, and supplemental Figure S1B and S1C, respectively). Distinct from 
these findings, and in agreement with a previous report [14], increased expression of miR-320, 
confined to GH secreting adenoma was apparent (supplemental Fig. S1A). In this case, and in contrast 
to other adenoma subtypes, the histone modification were those commonly associated with active 
genes (supplemental Fig S1B and S1C).  
Methylation status of CpG islands associated with HMGA transcript-targeting miRNA in 
primary pituitary adenomas: 
We next investigated the methylation status of the promoter associated CpG islands for each of the 
miRNA (miR-16, miR-26b, miR34b, miR-196-a2 and Let-7a) by pyrosequence analysis and relative 
to post-mortem normal pituitaries. In these cases and where sufficient primary tumour was available 
for analysis, low levels of methylation, between 4-12%, were detected for each of these miRNA with 
the exception of miR-26b (Supplemental Table S2). In this case we found that, 7 of 15 adenomas 
(~46%) irrespective of subtype showed increase in methylation (16-60%) relative to post-mortem 
normal pituitaries (~8%). However, the exception to this finding was the GH adenomas where we did 
not detect increase in CpG island methylation (Supplemental Table S2).  
Expression of HMGA transcript-targeting miRNA in GH3 cells: 
To gain insight into the functional impact of epigenetic modifications on miRNA expression we used 
the rodent pituitary cell line, GH3. Since previous studies have shown expression of hmga1 but not 
that of hmga2 in these cells [11] we focused our studies on hmga1.  Relative to normal pituitaries 
GH3 cells expressed significantly higher levels of hmga1 transcript as determined by RT-qPCR 
analysis (Figure 2A), however, and as we have shown previously in this cell line, expression of the 
bmp-4 transcript was significantly reduced relative to normal pituitary counterparts. [20] Stem-loop 
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RT-qPCR showed significantly reduced expression of the rodent homologues of, miR-16, miR-26b, 
miR-34b miR-196a-2 and let-7a in GH3 cells relative to normal pituitaries (Figure 2B). 
Epigenomic modifications associated with miRNA expression patterns in GH3 cells: 
ChIP analysis of histone modifications, associated with active genes, H3K9Ac, and repressed genes, 
H3K27Me3, in GH3 cell, showed these to be similar to those we observed in human pituitary 
adenomas. The findings for, miR-26b, miR-196a-2 and let-7a are presented in Figure 3 and for miR-
16 and miR-34b as supplemental data (supplemental data, Figure S2).  For each of these miRNA 
reduced transcript expression is associated with depletion of the modification associated with active 
gene, H3K9Ac, and enrichment of the modification associated with silenced genes, H3K27Me3 
(Figure 3B and 3C and supplemental Figure S2B and S2C respectively). For miR-320, the converse 
histone modifications are apparent and are consistent with the expression status of this miRNA in 
these cells (Supplemental Figure. S2B and-2C).   
Methylation status of CpG islands associated with miRNA expression in GH3 cells: 
For each of the miRNA investigated in this study (miR-16, miR-26b, miR34b, miR-196a-2 and Let-
7a) and as described for primary adenomas we determined their methylation status. For the CpG 
islands associated miR-16, miR-26b and Let-7a  there was no evidence for increased methylation (~5-
8%) in GH3 cells relative to normal rat pituitaries (Supplemental Table S2). However, the miR-196a-
2 and miR-34b associated CpG islands were methylated at ~80 and ~50% respectively (>80%) in 
GH3 cells. In these cases, drug challenges were ineffective or associated with marginal decrease in 
methylation at these miRNA associated CpG islands (Supplemental Table S2).  
Epidrug induced expression of miRNA in GH3 cells:  
GH3 cells were incubated, either alone or in combination, with an inhibitor of DNA methylation, 
zebularine and with the histone deacetylase inhibitor (HDACi), TSA. The findings for miR-26b, miR-
196a-2 and let-7a are shown in Fig. 3A and for miR-16, miR-34b and miR-320 in supplemental 
Figure S2A. In general, single drug challenges were either ineffective or led to marginal increase in 
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miRNA expression; however, combined drug challenges effectively increase expression of each of the 
miRNA with the exception of miR-320. For each of the miRNA, where their expression was increased 
it was associated with enrichment of the histone tail modification associated with active genes, 
H3K9Ac (Figures 3B and supplemental Figure S2B), and depletion of the modification associated 
with silent genes, H3K27Me3 (Figures 3C and supplemental Figure S2C). Distinct from these 
findings, epidrugs did not increase expression of miR-320; indeed, we observed a marginal decrease 
in transcript expression. However, in this case, epidrug challenges did not lead to significant change 
in histone tail modification associated with either active genes or repressed genes. For those miRNA 
where we determined CpG island methylation we observed a marginal (~20%) decrease in 
methylation in cells challenged with combined drugs (data not shown). These studies support a 
functional relationship between epigenetic modification and silencing or significant reduced 
expression of miRNA in pituitary cells. The data also shows that expression of these miRNA can be 
restored through epidrug mediated reversal of histone modifications.   
Epidrug induced, and miRNA mediated, suppression of HMGA1 expression in GH3 cells: 
The effects of epidrug-induced expression of endogenous miRNAs on the hmga1 transcript were 
assessed in GH3 cells. These studies (Figure 4A) show that drug challenges are associated 
with/responsible for a significant decrease in the hmga1 transcript relative to vehicle challenged cells. 
Furthermore, and as we showed previously, these epidrug challenges induced expression of the bmp-4 
gene. In these experiments and as we showed previously epidrug challenges (at the doses employed) 
did not lead to decrease in cell viability. [20] In addition to determining effects of epidrug-induced 
expression of endogenous miRNAs on the hmga1 transcript we also determined effect on hmga1 
protein. For quantitative analysis we used an ELISA specific for rodent hmga1. Figure 4B shows, in 
wild type GH3 cells, increase in hmga1 in GH3 cells relative to normal rat pituitaries and these 
findings are consistent with the transcript data shown in panel A. However, in GH3 challenged with 
epidrugs we observed a marginal but statistically significant decrease in hmga1 protein relative to 
GH3 challenged with vehicle alone.          
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DISCUSSION 
 
An expanding literature, germane to most tumour types, including those of pituitary origin, 
describes inappropriate expression of miRNA and apparent as either increase or decrease relative to 
their respective normal tissue counterparts. Although significant progress has been made toward 
identification of their target transcripts our understanding of the aberrations responsible for the 
inappropriate expression of miRNA per se are far from complete. However, and in common with 
protein-coding genes, miRNAs can be silenced through aberrant hypermethylation of CpG islands 
and/or by histone modifications. [18] 
Irrespective of pituitary adenoma subtype a significant proportion overexpress HMGA1 and 
HMGA2 [33,10,34,35], indeed, in the cohort we now describe, similar conclusions are apparent (data 
not shown). Convincing evidence for the role of these genes, and their protein products, in tumour 
evolution are provided through studies in transgenic mice, where, enforced expression of either 
hmga1 or hmga2 leads to the development of pituitary adenomas. [36-38] Although inappropriate 
expression of HMGA2 in a proportion of prolactinoma is associated with chromosome rearrangement 
or amplification [39] in other pituitary adenoma subtypes, overexpression of HMGA2 and also that of 
HMGA1, are not associated with these types of genetic perturbations. However, in these cases, loss or 
significantly reduced expression of target-specific miRNA, which contemporaneously target each of 
these transcripts, has been described. [11] Given our previous observations, and in particular for the 
BMP-4 gene in this tumour types [20] it seemed intuitive to characterize the epigenome associated 
with the miRNA targeting the HMGA1 and HMGA2 gene transcripts. We now show, for the first 
time for each of these  miRNA that loss or significantly reduced expression of, miR-16, miR-26b, 
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miR-34b miR196a-2 and let-7a is associated with histone tail modifications that are commonly 
associated with gene silencing. Contrary to these findings, expression of miR-320 is increased in GH 
secreting adenoma and depleted in other adenoma subtypes and similar findings of subtype specific 
expression patterns have been reported elsewhere. [14]  Moreover, and reinforcing these observations 
we now show that increased expression of miR-320 is associated with histone modification that 
characterize transcribed gene. Collectively, these findings would suggest that histone tail 
modifications impact on chromatin remodeling and miRNA expression. However a caveat associated 
with these observations is that the majority of adenomas in our investigation were macroadenomas. 
Indeed, and in this context, a single report has described miRNA expression that correlates with 
adenoma size. [40] Although this represents a single report the association between miRNA 
expression profiles and adenoma size are perhaps worthy of more detailed investigation.     
To directly assess the functional implication of histone tail modifications on miRNA 
expression we used the GH3 cell line as a model system. In this cell line and similar to our findings in 
primary adenomas, the rodent homologues of miR-16, miR-26b, miR-34b, miR196a-2 and Let-7a also 
show significantly reduced expression relative to normal pituitary and the contrary finding is apparent 
for miR-320.  ChIP analysis GH3 cell  again showed histone modifications similar to those apparent 
in primary human pituitary adenoma. Since we [19,41] and others [18,42-44]  have used epidrugs to 
restore expression of endogenous, epigenetically silenced mRNA and that of miRNA respectively, we 
exploited this approach in this report. For the first time, in a pituitary context we found combined drug 
challenges induced expression of the miRNA. In these cases, expression is associated with a reversal 
of the characterized histone modification toward those associated with active gene. Conversely, and 
reinforcing these findings, epidrugs did not lead to significant change in miR-320 expression or in the 
histone modifications associated with either active or silenced genes. The association between, drug-
induced re-expression of endogenously silenced miRNA and the enrichment of histone modification 
commonly associated with active genes strongly support an epigenetic mechanism as responsible for 
gene silencing.  
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As a functional end-pint we determined the effects of epidrug- induced re-expression of 
endogenous  miRNAs on their target transcript in GH3 cells. However, in these cases and since these 
cells do not express, hmga2 [11] we focused attention on hmga1. The studies showed that epidrugs, 
principally as combined challenges, are associated with a decrease in the hmga1 transcript levels 
relative to cell treated with vehicle alone. As control in these experiments, and as we reported 
previously [20], epidrug challenges induced robust re-expression of the bmp-4 gene. These findings 
would suggest that the decrease in hmga1 is not a consequences of drug-mediated cytoxicity or a 
generalized consequences of epidrug-induced miRNA expression. While similar observations, with 
respect to decreased expression  of  HMGA1 and HMGA2 transcript, in MEG-01 cells and also for 
hmga1 transcript in GH3 cell have been reported previously.[11]  these authors employed 
heterologous expression vectors harbouring each of the precursor miRNA. [11] Moreover, in this and 
in subsequent reports ([14,45] they also provide evidence that enforced expression of miRNA impact 
on mRNA stability and inhibition of translation. Using a quantitative ELISA based assay, specific for 
rodent hmga1, our data also shows that epidrugs lead to decrease in hmga1 protein. Taken together 
these findings would support the conclusion that, epidrug-induced and miRNA-mediated decrease in 
hmga1 is consequent to hmga1 transcript degradation and inhibition of translation. However, although 
technical limitations precluded us from determining the relative or absolute contribution of each of 
these pathways, our conclusions are reinforced by the independent approaches that reach similar 
conclusions and described above. [11,14,45]   
Thus far, investigations characterizing the inappropriate expression of miRNA in the genesis of 
pituitary adenomas has already led to the identification of subtype-specific miRNA profiles 
[46,47,16], identification of miRNA that show correlations with tumour size [40] or are predictive of 
tumor sensitivity and or response to therapeutic interventions. [47,16]  and have been subject to recent 
and extensive review, [48-51]. Still more recent studies have focused on the target transcripts for these 
miRNA. Future studies and treatment strategies offer significant promise in the context of epidrug 
induced re-expression of silenced miRNA either alone or in combination with more conventional 
therapeutic options. However, whiles these types of approach, particularly in a pituitary context are 
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attractive their effectiveness, either alone or in combination with conventional therapies, has not thus 
far been assessed in patient or indeed in animal models. Thus, necessary studies, initially in animal 
models will be required in these cases to address not only efficacy but also specificity and potential 
issues of cytoxicity. Indeed, and in this context, some of these issues have been subject to recent 
review (52). More recent reports that in this case identify targets of  miRNA that themselves play key 
roles or are central regulators of pathways that include, as example protein kinase Cδ and PTEN-AKT 
respectively might offer alternate indirect approaches [16,15]. In these cases investigators identified 
previously unknown, but what would appear to be novel targets that may represent pathways for more 
direct therapeutic interventions. 
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Figure Legends 
Figure 1. Expression and histone tail modifications associated with HMGA-targeting miRNA in 
human pituitary adenomas. (A) From left to right, quantitative RT-PCR of miR-26b, miR-196a-2 
and let-7a in non-functioning (NF), prolactinoma (P), corticotrophinoma (A) and growth hormone 
secreting adenomas (GH). Expression is reported relative to the mean of three post-mortem pituitaries, 
where the mean value is expressed as equal to 1 and where the individual values were within 10% of 
each other. Each bar represents the mean value ± SEM from three independent experiments performed 
in triplicate. (B) Chromatin immunoprecipitation analysis (ChIP) for the histone tail modification 
associated with active genes, H3K9Ac. Adenomas, and three post-mortem normal pituitaries, are 
those shown in panel A and enrichment in each case is relative to input chromatin. (C) ChIP analysis 
of adenomas and post-mortem normal pituitaries shown in panels A and B, for the histone tail 
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modification associated with silenced gene, H3K27Me3. In panels B and C each bar represents the 
mean value ± SEM from three independent experiments performed in triplicate. 
Figure 2.  Expression of the hmga1 transcript, and of hmga1- and hmga2- targeting miRNA, in 
GH3 cells. (A) Quantitative RT-PCR analysis of hmga1 and bmp-4 transcript expression in GH3 
cells.   Expression is reported relative to the mean of three normal rat pituitaries (NRP), where the 
mean value is expressed as equal to 100%. Each bar represents the mean value ± SEM from three 
independent experiments performed in triplicate. (B) RT-qPCR analysis of, miR-16, miR-26b, miR-
34b miR-196a-2 and let-7a in GH3 cells where each of the miRNA are shown relative to their 
expression in normal rodent pituitary counterparts, set at 100%,. Each bar represents the mean value ± 
SEM from three independent experiments performed in triplicate.  
Figure 3 Epidrug mediated effects on hmga1 targeting miRNA (A) From left to right, expression 
of miR-26b, miR-196a-2 and let-7a in GH3 cells as determined by RT-qPCR and relative to normal 
rat pituitaries (NRP). Expression was determined in the absence or presence of the epidrugs, 
zebularine (Zeb) and trichostatin A (TSA) either alone or in combination. Doses of drugs are shown 
on the x axis. Expression is reported relative to the mean of three normal rat pituitaries (NRP), where 
the mean value was expressed as equal to 100% and where each bar represents the mean value ± SEM 
from three independent experiments performed in triplicate. Panels B and C  show the ChIP analysis 
of the cells shown in panel A, where panel B is the modification associated with active gene, H3K9Ac 
and panel C is the modification associated with silencing, H3K27me3. Each bar represents the mean 
value ± SEM from three independent experiments performed in triplicate. Data was analyzed for 
significance by one-way ANOVA with Dunnett’s multiple comparison post-test. **, P < 0.01; ***, P 
< 0.001; ****, P < 0.0001 versus vehicle challenged GH3 cells. 
Figure 4  Epidrug mediated inhibition of hmga1 expression in GH3 cells. (A) GH3 cells were 
challenged with epidrugs as described in Figure 3 and expression of the hmga1 and bmp-4 transcript 
determined by RT-qPCR analysis. (B) ELISA analysis for rodent hmga1 protein in NRP and GH3 
cells following the challenges shown in the figure legend. Transcript expression is reported relative to 
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the mean of three normal rat pituitaries (NRP), where the mean value is expressed as equal to 100% 
and where each bar represents the mean value ± SEM from three independent experiments performed 
in triplicate. For the ELISA studies, statistical analysis is relative to the expression of hmga1 in GH3 
vehicle control and where each bar represents the mean value ± SEM from three independent 
experiments performed in duplicate. In panels A and B, data was analyzed for significance by one-
way ANOVA with Dunnett’s multiple comparison post-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
****, P < 0.0001 versus vehicle challenged GH3 cells. Normal rat pituitaries, unfilled bars. GH3 cells 
in the presence and absence of epidrugs, filled bars. 
Supplemental Figures 
Figure S1. Expression and histone tail modifications associated with HMGA-targeting miRNA 
in human pituitary adenomas. (A) From left to right, quantitative RT-PCR of miR-16, miR34b and 
miR-320 in non-functioning (NF), prolactinoma (P), corticotrophinoma (A) and growth hormone 
secreting adenomas (GH). Expression is reported relative to the mean of three post-mortem pituitaries, 
where the mean value was expressed as equal to 1. Each bar represents the mean value ± SEM from 
three independent experiments performed in triplicate. (B) Chromatin immunoprecipitation analysis 
(ChIP) for the histone tail modification associated with active genes, H3K9Ac. Adenomas, and three 
post-mortem normal pituitaries, are those shown in panel A and enrichment in each case is relative to 
input chromatin. (C) ChIP analysis of adenomas and post-mortem normal pituitaries shown in panels 
A and B, for the histone tail modification associated with silenced gene, H3K27Me3. In panels B and 
C each bar represents  mean value ± SEM from three independent experiments performed in triplicate. 
Figure S2 Epidrug mediated effects on hmga1 targeting miRNA (A) From left to right, expression 
of miR-16, miR-34b and miR-320 in GH3 cells as determined by RT-qPCR and relative to normal rat 
pituitaries (NRP). Expression was determined in the absence or presence of the epidrugs, zebularine 
(Zeb) and trichostatin A (TSA) either alone or in combination. Doses of drugs are shown on the x 
axis. Expression is reported relative to the mean of three normal rat pituitaries (NRP), where the mean 
value was expressed as equal to 100% and where each bar represents the mean value ± SEM from 
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three independent experiments performed in triplicate. Panels B and C  show the ChIP analysis of the 
cells shown in panel A, where panel B is the modification associated with active gene, H3K9Ac and 
panel C is the modification associated with silencing, H3K27me3. Each bar represents the mean value 
± SEM from three independent experiments performed in triplicate. Data was analyzed for 
significance by one-way ANOVA with Dunnett’s multiple comparison post-test. **, P < 0.01; ***, P 
< 0.001; ****, P < 0.0001 versus NRP. 
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